Method for predicting cerebral metastasis lesion foci in metastatic brain injury patients |
|||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Method for predicting cerebral metastasis lesion foci in metastatic brain injury patients (RU 2300109):
Method for predicting extracranial metastases development in patients having metastases in brain / 2297005
Method involves determining adrenal glands cortex hormone cortisol content in blood. At its level below the bottom border of the norm making from 260.0 up to 450.0 nmole/l, within the limits of cortisol concentration fluctuations from 70.0 to 240.0 nmole/l, extracranial metastases development are predicted to occur in 1-3.5 months after primary examination.
Method for predicting physical growth and development of small children / 2291444
Method involves determining triiodothyronine content in peripheral blood serum of children of the second half-year of life having perinatal central nervous system injury manifestations and no signs of hypothyroidism. The value being equal to 0.69±1.34 ng/ml, the children are predicted to have small height to the third year of life.
 Method for carrying out monitoring of diabetes mellitus patients state and neurological and vascular complications development / 2291437
Method involves determining immune reactivity of blood serum with respect to insulin, to anti-insulin antibodies or their antigen-binding fragments, to anti-anti-insulin antibodies binding the antibodies to insulin and antigens to growth factor or their antigen-binding fragments and ANCA antigen. Blood serum immunoreactivity increase with respect to parameters under measurement relative to norm is used for determining diabetes mellitus neurological and vascular complications development.
 Method for predicting the phases of stress states / 2288475
In patient's blood one should detect the concentration of cortisol and fertile factors α2-microglobulin (AMGF), trophoblastic β1-1-glycoproteide (TBG) and α1-placental microglobulin (PAMG-1). The phases of stress states should be diagnosed by the coefficient calculated due to dividing the sum of AMGF and TBG concentrations by the sum of PAMG-1 and cortisol concentrations, moreover, the concentration should be expressed in % against average values in healthy persons. Coefficient's value being equal to 1.0-11 corresponds to the norm; at its value being 1.2-1.5 one should diagnose the phase of anxiety; at 0.7-0.9 - the phase of resistance; at 0.2-0.6 - the phase of exhaustion. The innovation provides the chance to program the flow of pathological process more accurately.
Method for predicting the development of gastrointestinal tract paresis in patients with vertebral traumas / 2286089
In patients with vertebral traumas for about 2-3 h after lesion one should simultaneously determine the level of hormone cortisol, malonic dialdehyde (MDA) in blood serum, and, also, the value of total bioelectric activity (TBEA) of gastrointestinal tract (GIT) and at cortisol values being 981.7 nM/l and higher, and MDA values - 8.35 mM/l and higher and values of TBEA being 387.75 mcV and lower it is possible to predict the development of GIT paresis.
Method for predicting the development of stress reactions in early neonatal period in neonatals born in females with urogenital infection / 2284526
In serum of peripheral blood in pregnant women in trimester III of pregnancy period it is necessary to determine serotonin concentration. The flow of stress reactions in early neonatal period in neonatals should be predicted at serotonin level being above 0.1 mcg/ml. Application of the present method provides the opportunity for earlier prediction of the development of stress reactions in neonatals in early neonatal period.
Method of prognosing generalization of process in children and adolescents with osteal sarcoma / 2282195
Method provides for early prognosis of generalization disease due to most wide biological action of thyroidal hormones regulating principal stages of metabolic processes in body and influencing proliferation velocity and functions of nervous and immune systems, whose status, in turn, greatly determines state of antitumor résistance. Method is characterized by performing complex antitumor treatment and biochemical investigation and in patients undergone complex treatment with complete clinical and laboratory remission level of free fraction of thyroidal hormone triiodothironine is determined in blood. When this level lies within a range of 4.0 to 5.2 pmol/ml, preservation of remission during 6 to 24 month is forecasted and, at the level 5.8 to 7.4 pmol/ml, generalization of malignant process within period of 1 to 3 months is expected.
Method for diagnosing obliterated form of congenital adrenal gland cortex hyperplasia / 2279090
Method involves carrying out test with adrenocorticotropic. Blood levels of 11-desoxycortisol (S), cortisol (F), cortisone (E) and corticosterone (B) are determined by means of high performance liquid chromatography. Ratios of cortisol-to-cortisone levels (F/E) and to 11-desoxycortisol level (F/S) are calculated. Corticosterone level being lower than 17 ng/l and 11-desoxycortisol level being greater than 7.0 ng/l with F/E<5 and F/S<16, obliterated form of congenital adrenal gland cortex hyperplasia is to be diagnosed.
Method for predicting relapses in skin melanoma patients / 2275637
Method involves measuring daily estrone, estradiol and estriol excretion in women of reproductive age. Relation between estriol excretion and total amount of estrone and estradiol excretion after treatment and at control examination stage is calculated. The value being found to grow, relapse is predicted to occur in 11-12 months after the treatment.
Method for predicting bronchial asthma clinical development severity in adolescent patient at puberty transition time / 2273856
Method involves determining thyroid gland hormone of triiodothyronine (T3 in IU/l) and thyroxin (T4 in IU/l), pituitary hormones - thyrotropic hormone (TTH in IU/l), follicle-stimulating hormone (FSH in IU/l) and luteinizing hormone (LH in IU/l) concentration using radio isotope method and physical adolescent growth and development level with somatometric type being equal to 1 in microsomatic type cases, 2 in mesosomatic type cases and 3 in macrosomatic type cases. Discriminant function is determined in male adolescent case as D=19.535x(T3)+3.973x(T4)-27.38x(TTH)-11.028x(1.2 or 3)-307.473x(FSH)-17.585x(LH). The discriminant function value D>116.44 being the case, worsening bronchial asthma clinical course is predicted. D<116.44 being the case, bronchial improving asthma clinical course is predicted. Discriminant function is determined in female adolescent case as D=-4.908x(T3)-0.052x(T4)-0.355x(TTH)-3.166x(1.2 or 3)-0.769x(FSH)-0.144x(LH). The discriminant function value D>-24.23 being the case, worsening bronchial asthma clinical course is predicted. D<-24.23 being the case, improving bronchial asthma clinical course is predicted.
Method for differential diagnostics of mammary diseases in men / 2244308
The present innovation deals with biochemical trials: before the onset of therapy in men one should detect blood content of thyroid hormone - free thyroxine - and at its level being 10.3-12.9 pmol/l one should diagnose mammary cancer, at the level of free throxine being 18.7-31.0 pmol/l - one should predict gynecomastia. The method enables to detect the direction of pathological process and carry out due correction of therapy tactics in men with either gynecomastia or mammary cancer.
Method for predicting the delay of intrauterine fetal development / 2246733
The method deals with studying blood serum of pregnant woman to detect the content of insulin-like growth factor (IGF) and vascular-endothelial growth factor (VEGF) and calculate the coefficient of their ratio: at its value being equal to 28.5 and lower it is possible to diagnose the delay of fetal development.
Method for differential diagnostic of chronic hepatitis and hepatic cirrhosis / 2254577
Thyroglobulin content is determined in blood serum using enzyme immunoassay. When thyroglobulin level is increased by 2 times and more compared in contrast with normal one chronic hepatitis is diagnosed, and when thyroglobulin level is decreased by 1.5-2.5 times in contrast with normal one hepatic cirrhosis is diagnosed.
Method for evaluating combined schizophrenia treatment based on atypical antipsychotic drugs and rations and electroconvulsive shock therapy / 2256181
Method involves determining dehydroepiandrosterone sulfate concentration in blood serum. Its growth above 30% when compared to the initial one being observed, treatment efficiency is determined as negative.
Method for diagnosing obliterated forms of congenital suprarenal gland cortex hyperplasia / 2261447
Method involves applying high effectiveness liquid chromatography for determining cortisol, cortisone 11-deoxycorticosterone, 11-deoxycortisone concentration in blood and free cortisol and free cortisone excretion with urine. Ratios of F/E and FF/FE are calculated, where F is the cortisol level in blood; E is the cortisone level in blood; FF is the free cortisol excretion with urine and FE is the free cortisone excretion with urine. The cortisol level in blood not exceeding norm and at least two of three signs: F/E ratio reduction by 25% and more, FF/FE ratio reduction by 25% and more, free cortisol excretion with urine being equal to 25% and more, obliterated forms of congenital suprarenal gland cortex hyperplasia is diagnosed. Corticosterone level in blood growing by 50% and higher, 21-hydroxylase defect is considered to be the case. 11-deoxycorticosterone and/or 11-deoxycortisone concentration in blood being et or greater than 50%, 11β-hydroxylase defect is considered to be the case.
 Method for diagnosing atrophic gastritis cases / 2262706
Method involves making pepsinogen 1, gastrin and Helicopter pylori infection marker combinations analysis and making input of the obtained results into data processing means comprising operation system, means for receiving, transmitting and processing data. The mentioned data processing means is usable for comparing the measured concentration value of a substance under study to a threshold value associated to the substance under study and producing information as a response to comparison results and additionally to other entered data. A set and software are used for implementing the method.
Method for predicting relapse of mammary cancer / 2263319
In the course of surveying in menopausal women after complex therapy one should state the development of mammary cancer at decreased ratio of estriol concentration to the sum of estrone and estradiol urinary concentrations from 1.68±0.23 in relapse-free patients up to 0.74±0.12 - in patients living without relapses for less than a year, up to 0.65±0.13 in patients living without relapse from 2 up to 6 years and up to 0.50±0.10 in patients with relapse-free period from 6 to 10 years. The innovation provides pre-clinical detection of mammary cancer relapse.
Method for predicting fetoplacental insufficiency in pregnant women with thyroid diseases / 2263919
Except detecting placental lactogen in blood serum one should study the content of alphafetoprotein. At placental lactogen content being below 75% against the norm and content of alphafetoprotein below 70% against the norm it is possible to conclude upon availability of fetoplacental insufficiency.
Method for predicting cholecystitis and cholelithiasis / 2263920
While diagnosing cholecystitis and cholelithiasis due to ultrasound testing one should additionally study blood plasma and bile to detect there the content of prostaglandins PGE2 and PGF2α. At PGE2/PGF2α ratio in blood plasma being equal to 6 and more, and, also, at decreased level of biliary cholecystokinin-pancreosimin by 38% and more, biliary PGE2 by 59% and more and increased level of biliary prostaglandin PGF2α by 5.9 times and more against the norm one should diagnose chlecystitis and cholelithiasis. The innovation enables to detect the above-mentioned diseases at earlier stage.
Method for predicting powerless labor in pregnant nodular goiter surgically treated on goiter occasion during pregnancy under medical supervision / 2273456
Method involves determining thyroid gland node diameter and thyrotropic hormone by applying ultrasonic examination approach. Histological examination is carried out with conclusion concerning morphologic nature being obtained like nodular colloid proliferating goiter or thyroid gland adenoma. Diagnostic index Σ is calculated from formula Σ=0.49*K1+0.07*K2-0.5*K3+1.76*K4-1.53, where K1 is the thyroid gland node diameter; K2 is the TTH concentration; K3 is the nodular colloid proliferating goiter index equal to 1 or 0; K4 is the thyroid gland adenoma index equal to 1 or 0. Diagnostic index Σ being less than zero, conclusions concerning powerless labor threat is to be drawn.
|
FIELD: medicine. SUBSTANCE: method involves determining thyroxin hormone concentration in cerebral metastasis-ill patient blood prior to treatment beginning. Its concentration being found within the limits of 68.0-115.0 nmole/l, 1 to 3 metastatic lesion foci are predicted to be available. The concentration being from 38.0 to 50.0 nmole/l, more than 4 p metastatic lesion foci are predicted to be available. EFFECT: high forecasting accuracy both in primary examination period, and when carrying out treatment. 1 tbl
The invention relates to medicine, namely to biochemical research in Oncology, and can be used to assess the prevalence of metastatic process in the brain in cancer patients. One of the factors in assessing the extent of process in patients with metastases in the brain is the determination of the number of metastatic foci. With this purpose, the patients performed a CT scan, which is currently the most accurate method to determine their number. The lack of equipment in medical institutions specified equipment and the high cost of research in some cases may prevent the timely clarification of the prevalence of the disease. However, such information is appropriate and necessary already at the initial examination of patients with metastatic brain disease, because treatment strategy for patients with this cancer depends not only on the localization and size of the lesions, but also from their number. This situation determines the necessity of finding more affordable additional laboratory tests that reliably can be used for primary screening of patients, as well as when working with high-risk groups. The endocrine system, cha is the surrounding area of the thyroid gland, play an important role in the mechanisms of adaptation and resistance of the organism not only in normal but also in pathological processes. This role is due to the involvement of thyroid hormones in the regulation of all types of metabolism in the body - protein, carbohydrate and fat and, consequently, involved in many physiological functions. The development of a malignant tumor and its metastases is accompanied by effects on the activity of various body systems, including the endocrine. This makes it advisable to search for such hormonal indicators which change in blood may correlate with the number of metastatic lesions in the affected organ. There is a method of predicting the course of cancer (see patent No. 2018835 from 11.11.90, bull. No. 16 from 30.8.94 g). The invention consists in that in lymphocytes and neutrophils in the blood determine the content of histamine within 4-45 days, then calculate the ratio of the index in lymphocytes to measure neutrophil and when the ratio over 0.9 predict complication of the disease in the appearance of recurrence and metastases. The disadvantage of this method is the need for multiple studies over a long period of time. In addition, predicting complications of the disease using the proposed show is La, it is impossible to assert not only the appearance of it is mesmerizing, but also their localization. There is a method of diagnosis of metastasis of kidney cancer in men, chosen as a prototype (see ed. mon. No. 1211915 from 20.07.83). The authors of this method suggest using the concentration in the urine hormone Androsterone as a criterion associated with the development of metastasis of kidney cancer. The hormone daily urine examined after surgical treatment of patients with cancer localization. While reducing its level by 75-90% compared to the norm diagnosed with metastatic kidney cancer. The disadvantage of this method is that it is designed for the detection of metastases in patients after removal of the primary lesion and may not be informative on the background of existing malignant process. In addition, this method serves to identify extracerebral metastases localization. The aim of the invention is forecasting the number of metastatic foci in the brain. This objective is achieved in that in patients with cerebral metastases before treatment to determine the blood content of the hubbub of thyroxine and its concentration in the range from 68,0 to 115,0 nmol/l predict the presence of from 1 to 3 metastatic lesions, and when concentric and from 38,0 to 50.0 nmol/l predict the presence of more than 4 foci of metastasis. The invention of "a Method for predicting cerebral metastatic foci in patients with metastatic brain" is new, because it is not known from the level of medicine in the assessment of the extent of the metastatic process in cancer patients with metastases to the brain. The novelty of the invention lies in the fact that in patients with cerebral metastases before treatment to determine blood hormone thyroxine and its concentration in the range from 68,0 to 115,0 nmol/l predict the presence of from 1 to 3 metastatic lesions, and at a concentration of from 38,0 to 50.0 nmol/l predict the presence of more than 4 lesions. The invention involves an inventive step as an oncologist and neurosurgeon is not obvious from the level of development of medicine in the field of quantitative assessment of the extent of the metastatic process by biochemical studies of the hormonal status of the patients. The invention is industrially applicable as it can be reproduced in health care in health care institutions for the diagnosis and treatment of cerebral metastases in cancer patients, cancer research institutes, oncologic dispensaries. A method for predicting the quantity of cerebral Mets oticheskih foci in patients with metastases in the brain is carried out as follows. The study included 9 patients with metastases in the brain that evolved at different times after radical treatment of primary tumors of the breast, lung or melanoma. When screening for delacerna stage with the help of computer tomography in patients identified different extent of the metastatic process: in 6 out of 9 people found from 1 to 3 metastatic foci, and in the remaining 3 patients - more than 4 lesions (table).
At the same time in all patients was determined by blood levels of the thyroid hormone thyroxine conventional radioimmunoassay method. Then the level of the hormone was analyzed in relation with the number of metastatic foci. It is established that when they number in the brain from 1 to 3, the concentration of thyroxine in the blood of patients ranges from 68,0 to 115,0 nmol/l and is within its oscillations in healthy people, the constituents from 70,0 to 145,0 nmol/L. In contrast, when there are more than 4 lesions secondary lesions of the brain hormone in all cases is reduced and ranges from 38,0 to 50.0 nmol/L. Therefore, low level of thyroxine in the blood - 38,0-50.0 nmol/l combined with a large number - more than 4 - foci of metastatic lesions of the brain, while the normal concentration of the hormone detected in patients with a smaller number of foci from 1 to 3-X. The specific examples of the application of the Method for predicting cerebral metastatic foci in patients with metastatic brain". Clinical example No. 1. Patient K., born in 1956, case history No. 5898/R. He enrolled in the Department of neurosurgery, RNII 26.03.2004 was diagnosed with Cancer of the left breast, T3N1M1, with metastatic lesions of the vertebral bodies of the thoracic spine, liver, INR is the natural enemy of metastatic lesions of the brain, stage IV. Multiple metastatic brain lesion (more than 4 foci) in this patient was identified using CT-studies from 24.03.2004, Before the start of drug therapy according to the method developed by us, the patient, a study was conducted content of thyroxine in the blood, which was reduced to 44 nmol/L. Thus, in this patient the level of thyroxine in the blood is not reaching the lower limit of normal (fluctuations in the rate from 70,0 to 145,0 nmol/l), associated with the presence of multiple metastatic lesions brain more than four. Clinical example No. 2. Patient B., born in 1952, case history No. 22842/so He enrolled in the Department of neurosurgery, RNII 6.12.2004, for operative treatment with a diagnosis of Peripheral cancer of the left lung with metastatic mediastinal lymph nodes and brain (right and left parietal lobe). According to CT brain from 2.12.2004, found 2 of metastasis in both parietal lobes of the brain, sizes 3 and 4 cm in diameter. Before performing surgery in a patient study of the content of thyroxine in the blood, which was equal to 115,0 nmol/L. Thus, in this patient the level of thyroxine in the blood is in the border of physiological fluctuations in the concentration of g is Ramona normal, components from 70,0 to 145,0 nmol/l, and is associated with the presence of 2 metastatic lesions of the brain. 9.12.2004, the patient simultaneously were performed 2 osteoplastic craniotomy in both parietal regions with radical removal of metastatic tumors. Surgery confirmed the presence of 2 metastatic lesions of the brain. Technical and economic efficiency "Method for predicting cerebral metastatic foci in patients with metastatic brain" is that the determination of thyroxine in the blood of patients with this pathology is the criterion prevalence of metastatic process in the brain. Computed tomography, which is currently the most accurate method of determining the number of metastatic lesions, can not completely replace the diagnosis on the basis of biochemical studies, as available to all medical institutions, has a high cost of research and, in some cases, may prevent the timely clarification of the prevalence of the disease. Getting an affordable, fast information appropriate and necessary already at the initial examination of patients with metastatic brain disease, because the tactics of treatment of the Aulnay depends not only on the localization and size of lesions, but from their number. We offer diagnostics can be used during the initial screening of patients and when working with high-risk groups. A method for predicting cerebral metastatic foci in patients with metastatic lesions of the brain, including biochemical, characterized in that in patients with cerebral metastases before treatment to determine blood hormone thyroxine and its concentration from 68,0 to 115,0 nmol/l predict the presence of from 1 to 3 metastatic lesions, and at a concentration of from 38,0 to 50.0 nmol/l predict the presence of more than 4 foci of metastasis.
|
||||||||||||||||||||||||||||||||